(NASDAQ: ABCL) Abcellera Biologics's forecast annual revenue growth rate of -14.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.99%.
Abcellera Biologics's revenue in 2026 is $67,857,000.On average, 15 Wall Street analysts forecast ABCL's revenue for 2026 to be $11,731,134,971, with the lowest ABCL revenue forecast at $7,041,881,838, and the highest ABCL revenue forecast at $38,410,264,570. On average, 14 Wall Street analysts forecast ABCL's revenue for 2027 to be $11,065,814,316, with the lowest ABCL revenue forecast at $6,401,710,762, and the highest ABCL revenue forecast at $21,571,478,941.
In 2028, ABCL is forecast to generate $14,446,309,540 in revenue, with the lowest revenue forecast at $6,401,710,762 and the highest revenue forecast at $41,633,983,203.